rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Stephanie Okey

Director

Company insider

Files Form 4 as: Director, Crinetics Pharmaceuticals; Director, PTC Therapeutics; Director, Catalent; Director, Albireo Pharma.

Every Form 4 they filed

In numbers

Trades disclosed
95
Buys
0
Sells
9
Bought
$0
Sold
$5.0M
Companies
4
Companies where not an officer
4
First trade
8 Jun 2018
Last trade
1 Sep 2026
Last filed
1 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Crinetics PharmaceuticalsDirector · Biotechnology · last 1 Sep 20260 buys · 3 sells
PTCT PTC TherapeuticsDirector · Biotechnology · last 10 Mar 20260 buys · 6 sells
CatalentDirector · last 18 Dec 20240 buys · 0 sells
Albireo PharmaDirector · last 2 Mar 20230 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
30Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$544K6,400 at $85.00filing
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$504K5,925 at $85.00filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.5M25,000 at $60.85filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.5M25,000 at $60.85filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$772K12,500 at $61.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.68filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$504K12,500 at $40.29filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$545K10,350 at $52.67filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$478K9,730 at $49.13filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$772K12,500 at $61.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.68filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$504K12,500 at $40.29filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$545K10,350 at $52.67filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$478K9,730 at $49.13filing
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$544K6,400 at $85.00filing
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$504K5,925 at $85.00filing
18 Jun 2026filed 22 Jun 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code A—5,925 at $0.00filing
18 Jun 2026filed 22 Jun 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—9,730 at $0.00filing

Sectors

Health Care9

Buys in green, sells in red, by the company’s sector.

Related people

Michael SchmertzlerDirector · Director at Ptc Therapeutics, filing Form 4 there in the last year
Mark Elliott BouldingExec. VP and CLO · Exec. VP and CLO at Ptc Therapeutics, filing Form 4 there in the last year
Glenn Steele Jr.Director · Director at Ptc Therapeutics, filing Form 4 there in the last year
Camille L. BedrosianChief Medical Officer · Director at Crinetics Pharmaceuticals, filing Form 4 there in the last year
Matthew K. FustDirector · Director at Crinetics Pharmaceuticals, filing Form 4 there in the last year
Matthew B. KleinChief Executive Officer · Also traded PTCT in the last 90 days
Donald J. TrumpPresident · Also traded PTCT in the last 90 days